NeurAxis Reports Record First Quarter 2026 Financial Results Driven by 80% Year Over Year Revenue Growth

NeurAxis, Inc. reported an 80% year-over-year revenue growth for Q1 2026, driven by increased insurance coverage and the implementation of a Category I CPT® code for its product IB-Stim. The company achieved revenues of $1.6 million, up from $896 thousand in Q1 2025, with a gross margin improvement to 86.4%. Operating expenses rose due to higher selling costs but were offset by a significant increase in gross profit. NeurAxis remains focused on advancing its neuromodulation therapies for chronic conditions.